A. T. V. Terwisscha van Scheltinga

发表

Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer.

Vasilis Ntziachristos, Maximilian Koch, Sabrina Oliveira, 2016, Cancer research.

Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study

Vasilis Ntziachristos, Sabrina Oliveira, Bert van der Vegt, 2016, Clinical Cancer Research.

Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use.

E. D. de Vries, J. Kosterink, W. Nagengast, 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer.

E. D. de Vries, J. Kosterink, C. Schröder, 2014, European journal of cancer.

Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab

E. D. de Vries, S. de Jong, M. L. Lub-de Hooge, 2016, Oncotarget.

89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors

E. D. de Vries, G. Meneses‐Lorente, C. Adessi, 2017, Clinical Cancer Research.

89Zr-Onartuzumab PET imaging of c-MET receptor dynamics

E. D. de Vries, M. L. Lub-de Hooge, A. T. V. Terwisscha van Scheltinga, 2017, European Journal of Nuclear Medicine and Molecular Imaging.

ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1

Jeffrey T. Lau, Judith E. Flores, Simon-Peter Williams, 2016, Oncotarget.

Preclinical Efficacy of an Antibody–Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET

Simon-Peter Williams, R. Firestein, A. Ogasawara, 2016, Molecular Cancer Therapeutics.

Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study

S. H. van der Burg, M. Welters, S. Santegoets, 2020, Journal for ImmunoTherapy of Cancer.

Antibody positron emission tomography imaging in anticancer drug development.

E. D. de Vries, J. Gietema, Simon-Peter Williams, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting.

E. D. de Vries, H. Timmer-Bosscha, F. Bensch, 2014, Pharmacology & therapeutics.

MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells

E. D. de Vries, R. Fehrmann, S. de Jong, 2019, The Journal of pathology.

Fluorescence-guided tumor detection with a novel anti-EpCAM targeted antibody fragment: Preclinical validation.

Leonora S. F. Boogerd, A. Valentijn, P. Kuppen, 2019, Surgical oncology.

Molecular Fluorescence Endoscopy Targeting Vascular Endothelial Growth Factor A for Improved Colorectal Polyp Detection

Vasilis Ntziachristos, Maximilian Koch, Gooitzen M van Dam, 2016, The Journal of Nuclear Medicine.

Intraoperative Near-Infrared Fluorescence Tumor Imaging with Vascular Endothelial Growth Factor and Human Epidermal Growth Factor Receptor 2 Targeting Antibodies

Vasilis Ntziachristos, Gooitzen M van Dam, Wouter B Nagengast, 2011, The Journal of Nuclear Medicine.

Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake.

Marjolijn N Lub-de Hooge, Elisabeth G E de Vries, Erik T Garbacik, 2013, Cancer research.

In Vivo Visualization of MET Tumor Expression and Anticalin Biodistribution with the MET-Specific Anticalin 89Zr-PRS-110 PET Tracer

E. D. de Vries, J. Kosterink, L. Audoly, 2014, The Journal of Nuclear Medicine.

Biodistribution and PET Imaging of Labeled Bispecific T Cell–Engaging Antibody Targeting EpCAM

E. D. de Vries, J. Kosterink, M. Friedrich, 2016, The Journal of Nuclear Medicine.

A zwitterionic near-infrared fluorophore for real-time ureter identification during laparoscopic abdominopelvic surgery

B. G. Sibinga Mulder, A. Valentijn, A. Vahrmeijer, 2019, Nature Communications.

First-in-Human Assessment of cRGD-ZW800-1, a Zwitterionic, Integrin-Targeted, Near-Infrared Fluorescent Peptide in Colon Carcinoma

A. Valentijn, A. Vahrmeijer, J. Frangioni, 2020, Clinical Cancer Research.

Human Epidermal Growth Factor Receptor 3–Specific Tumor Uptake and Biodistribution of 89Zr-MSB0010853 Visualized by Real-Time and Noninvasive PET Imaging

E. de Vries, J. Kosterink, C. Knuehl, 2017, The Journal of Nuclear Medicine.

89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment

E. D. de Vries, S. de Jong, M. L. Lub-de Hooge, 2017, mAbs.

ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody 89Zr-RG7116

E. D. de Vries, J. Kosterink, B. Bossenmaier, 2014, mAbs.

Towards clinically translatable NIR fluorescence molecular guidance for colonoscopy.

Vasilis Ntziachristos, Maximilian Koch, Panagiotis Symvoulidis, 2013, Biomedical optics express.